Sebteembar 8, 2025, InnoCare Pharma waxay ku dhawaaqday in HIBRUKA (orelabrutinib) ay ansixisay Hay'adda Sayniska Caafimaadka (HSA) ee Singapore si loogu daaweeyo bukaanada qaangaarka ah ee qaba lymphoma-ka aagga soo noqnoqda ama aan firfircoonayn (R/R MZL).
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
Lymphoma-ga aagga yar (MZL) waa lymphoma-ka aan ahayn Hodgkin's lymphoma (NHL) ee aan firfircoonayn kaas oo inta badan saameeya bukaanada da'da dhexe iyo waayeelka ah. Tirada sanadlaha ah ee MZL ayaa kor u kacaysa adduunka oo dhan. Ka dib daaweynta safka hore, bukaanada qaba R/R MZL ma haystaan ikhtiyaar daaweyn oo wax ku ool ah.
Bishii Abriil 2025, orelabrutinib waxay ka heshay Shiinaha oggolaansho daaweynta safka hore ee bukaanada qaba leukemia-da daba-dheeraatay (CLL) / lymphoma-ka yar ee lymphocytic (SLL). Orelabrutinib waxaa sidoo kale loo oggolaaday daawaynta saddex tilmaamood oo kale oo ku yaal Shiinaha, oo ay ku jiraan CLL/SLL oo soo noqnoqda iyo mid aan firfircoonayn (R/R), lymphoma-ka unugyada mantle-ka ee r/r (R/R MCL) iyo lymphoma-ka aagga marginal-ka ee r/r (R/R MZL), kuwaas oo dhammaantood lagu daboolay Liiska Dawooyinka Lacag-bixinta Qaranka ee Shiinaha.
Waxtarka, Badbaadada, iyo Caqliga Orelabrutinib Plus Obinutuzumab ee Daaweynta Nidaamsan - Lymphoma Aagga Madow: Daraasad Kooxeed oo la filayo ayaa muujisay in daraasadda oo dhan iyo inta lagu jiro daaweynta la bilaabayo, heerka jawaab celinta guud (ORR) uu yahay 100%. Saddex bukaan oo qaba jawaab celin qayb ahaan ah (PR) ka dib daaweynta la bilaabayo ayaa gaaray jawaab celin dhammaystiran (CR) inta lagu jiro dayactirka.
Baaritaannada ADCC waxay muujiyeen orelabrutinib oo ay weheliso nidaamka obinutuzumab oo kiciyay jawaabta ADCC ee ugu firfircoon khadadka unugyada TMD-8 iyo REC-1.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
Waqtiga boostada: Sebteembar-09-2025